These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 10602413

  • 1. Leukemogenesis by CBF oncoproteins.
    Friedman AD.
    Leukemia; 1999 Dec; 13(12):1932-42. PubMed ID: 10602413
    [Abstract] [Full Text] [Related]

  • 2. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K, Tanaka T, Kurokawa M, Imai Y, Ogawa S, Mitani K, Yazaki Y, Hirai H.
    Blood; 1998 Mar 01; 91(5):1688-99. PubMed ID: 9473235
    [Abstract] [Full Text] [Related]

  • 3. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C, Kim N, Hiebert S, Zhang DE, Tenen DG, Rowley JD, Nucifora G.
    Curr Top Microbiol Immunol; 1996 Mar 01; 211():243-52. PubMed ID: 8585955
    [Abstract] [Full Text] [Related]

  • 4. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F, Pisegna S, Diverio D.
    Haematologica; 1997 Mar 01; 82(3):364-70. PubMed ID: 9234595
    [Abstract] [Full Text] [Related]

  • 5. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins.
    Lou J, Cao W, Bernardin F, Ayyanathan K, RauscherIII FJ, Friedman AD.
    Oncogene; 2000 May 18; 19(22):2695-703. PubMed ID: 10851069
    [Abstract] [Full Text] [Related]

  • 6. AML1/CBFbeta transcription complex: its role in normal hematopoiesis and leukemia.
    Downing JR.
    Leukemia; 2001 Apr 18; 15(4):664-5. PubMed ID: 11368373
    [No Abstract] [Full Text] [Related]

  • 7. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias.
    Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, Nishida J, Yazaki Y, Shibata Y, Hirai H.
    Mol Cell Biol; 1995 May 18; 15(5):2383-92. PubMed ID: 7739522
    [Abstract] [Full Text] [Related]

  • 8. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G.
    Proc Natl Acad Sci U S A; 1996 Feb 20; 93(4):1642-7. PubMed ID: 8643684
    [Abstract] [Full Text] [Related]

  • 9. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
    Cuenco GM, Ren R.
    Oncogene; 2001 Dec 13; 20(57):8236-48. PubMed ID: 11781838
    [Abstract] [Full Text] [Related]

  • 10. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
    Miller JD, Stacy T, Liu PP, Speck NA.
    Blood; 2001 Apr 15; 97(8):2248-56. PubMed ID: 11290585
    [Abstract] [Full Text] [Related]

  • 11. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
    Zent C, Rowley JD, Nucifora G.
    Leukemia; 1997 Apr 15; 11 Suppl 3():273-8. PubMed ID: 9209363
    [Abstract] [Full Text] [Related]

  • 12. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
    Cuenco GM, Ren R.
    Oncogene; 2004 Jan 15; 23(2):569-79. PubMed ID: 14724585
    [Abstract] [Full Text] [Related]

  • 13. [Molecular pathogenesis of leukemias].
    Kurokawa M.
    Rinsho Ketsueki; 2009 Oct 15; 50(10):1382-8. PubMed ID: 19915346
    [No Abstract] [Full Text] [Related]

  • 14. AML1 interconnected pathways of leukemogenesis.
    Michaud J, Scott HS, Escher R.
    Cancer Invest; 2003 Oct 15; 21(1):105-36. PubMed ID: 12643014
    [Abstract] [Full Text] [Related]

  • 15. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1.
    Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G.
    Leukemia; 1999 Mar 15; 13(3):348-57. PubMed ID: 10086725
    [Abstract] [Full Text] [Related]

  • 16. Role of AML1/Runx1 in the pathogenesis of hematological malignancies.
    Kurokawa M, Hirai H.
    Cancer Sci; 2003 Oct 15; 94(10):841-6. PubMed ID: 14556655
    [Abstract] [Full Text] [Related]

  • 17. The role of the AML1 transcription factor in leukemogenesis.
    Lorsbach RB, Downing JR.
    Int J Hematol; 2001 Oct 15; 74(3):258-65. PubMed ID: 11721960
    [Abstract] [Full Text] [Related]

  • 18. The EVI1 gene in myeloid leukemia.
    Nucifora G.
    Leukemia; 1997 Dec 15; 11(12):2022-31. PubMed ID: 9447815
    [Abstract] [Full Text] [Related]

  • 19. Molecular basis of the t(8;21) translocation in acute myeloid leukaemia.
    Ohki M.
    Semin Cancer Biol; 1993 Dec 15; 4(6):369-75. PubMed ID: 8142622
    [Abstract] [Full Text] [Related]

  • 20. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
    Cuenco GM, Nucifora G, Ren R.
    Proc Natl Acad Sci U S A; 2000 Feb 15; 97(4):1760-5. PubMed ID: 10677531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.